Efficacy and safety of pegylated interferon α and ribavirin in patients monoinfected with HCV genotype 4

Abstract

Introduction Dual therapy (PegIFN and ribavirin) (DT) was the standard of care in patients infected with HCV genotype 4 (HCV-4) until 2014. Nowadays, new treatment options are available including interferon (IFN)-based and other IFN-free regimens. Aim To assess the efficacy (SVR24) and safety of DT and the selected predictor factors of SVR in HCV-4… (More)
DOI: 10.5114/pg.2018.74558

5 Figures and Tables

Topics

  • Presentations referencing similar topics